{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:01Z","timestamp":1790612101527,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00932-0","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:11:15Z","timestamp":1775751075000},"page":"1345-1355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Digital Monitoring of Patients with Generalized Myasthenia Gravis: A Prospective Pilot Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1919-9382","authenticated-orcid":false,"given":"Ana","family":"Vesperinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Rocaspana-Codana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reyes-Leiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Caballero-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Carbayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Collet-Vidiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Llans\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Turon-Sans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"4","key":"932_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263(4):826\u201334. https:\/\/doi.org\/10.1007\/s00415-015-7963-5.","journal-title":"J Neurol"},{"issue":"1","key":"932_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Vershuuren JJGM. Myasthenia Gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"932_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693\u20139. https:\/\/doi.org\/10.1002\/mus.26689.","journal-title":"Muscle Nerve"},{"issue":"1","key":"932_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mus.21713","volume":"42","author":"TM Burns","year":"2010","unstructured":"Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve. 2010;42(1):5\u201313. https:\/\/doi.org\/10.1002\/mus.21713.","journal-title":"Muscle Nerve"},{"key":"932_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-15","volume":"12","author":"A Br\u00e9dart","year":"2014","unstructured":"Br\u00e9dart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C. Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients\u2019 experience. Health Qual Life Outcomes. 2014;12:15. https:\/\/doi.org\/10.1186\/1477-7525-12-15.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"932_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139. https:\/\/doi.org\/10.1002\/mus.27476.","journal-title":"Muscle Nerve"},{"issue":"7","key":"932_CR7","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139. https:\/\/doi.org\/10.1212\/wnl.52.7.1487.","journal-title":"Neurology"},{"issue":"2","key":"932_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mus.26910","volume":"62","author":"T McPherson","year":"2020","unstructured":"McPherson T, Aban I, Duda PW, et al. Correlation of quantitative myasthenia gravis and myasthenia gravis activities of daily living scales in the MGTX study. Muscle Nerve. 2020;62(2):261\u20136. https:\/\/doi.org\/10.1002\/mus.26910.","journal-title":"Muscle Nerve"},{"key":"932_CR9","unstructured":"\u00abMyasthenia Gravis Foundation of America. MGFA 2012 Annual Report [Internet]. 2012. Available from: https:\/\/myasthenia.org\/wp-content\/uploads\/Portals\/0\/MGFA%202012%20Annual%20Report-%20Final.pdf\u00bb."},{"issue":"2","key":"932_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/mus.27987","volume":"69","author":"BB Recasens","year":"2024","unstructured":"Recasens BB, Bala\u00f1\u00e1-Corber\u00f3 A, Mart\u00ednez-Llorens JM, et al. Sound-based cough peak flow estimation in patients with neuromuscular disorders. Muscle Nerve. 2024;69(2):213\u20137. https:\/\/doi.org\/10.1002\/mus.27987.","journal-title":"Muscle Nerve"},{"issue":"1","key":"932_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000531224","volume":"7","author":"M Lootus","year":"2023","unstructured":"Lootus M, Beatson L, Atwood L, et al. Development and assessment of an artificial intelligence-based tool for ptosis measurement in adult myasthenia gravis patients using selfie video clips recorded on smartphones. Digit Biomark. 2023;7(1):63\u201373. https:\/\/doi.org\/10.1159\/000531224.","journal-title":"Digit Biomark"},{"issue":"6","key":"932_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mus.27243","volume":"63","author":"D Menon","year":"2021","unstructured":"Menon D, Alnajjar S, Barnett C, et al. Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: Assessment of a novel virtual myasthenia gravis index. Muscle Nerve. 2021;63(6):831\u20136. https:\/\/doi.org\/10.1002\/mus.27243.","journal-title":"Muscle Nerve"},{"issue":"12","key":"932_CR13","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1007\/s10072-021-05566-8","volume":"42","author":"D Ricciardi","year":"2021","unstructured":"Ricciardi D, Casagrande S, Iodice F, et al. Myasthenia gravis and telemedicine: a lesson from COVID 19 pandemic. Neurol Sci. 2021;42(12):4889\u201392. https:\/\/doi.org\/10.1007\/s10072-021-05566-8.","journal-title":"Neurol Sci"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1007\/s10072-022-05918-y","volume":"43","author":"F Pasqualin","year":"2022","unstructured":"Pasqualin F, Guidoni SV, Albertini E, Ermani M, Frangiamore R, Vanoli F, et al. Development and validation of the Myasthenia Gravis TeleScore (MGTS). Neurol Sci. 2022;43:4503\u20139. https:\/\/doi.org\/10.1007\/s10072-022-05918-y.","journal-title":"Neurol Sci"},{"issue":"1","key":"932_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/mus.27837","volume":"68","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Janssen MF, Tollenaar NH, et al. Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. Muscle Nerve. 2023;68(1):65\u201372. https:\/\/doi.org\/10.1002\/mus.27837.","journal-title":"Muscle Nerve"},{"issue":"5","key":"932_CR16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/mus.21142","volume":"38","author":"GI Wolfe","year":"2008","unstructured":"Wolfe GI, Barohn RJ, Sanders DB, McDermott MP. Comparison of outcome measures from a trial of Mycophenolate mofetil in myasthenia gravis. Muscle Nerve. 2008;38(5):1429\u201333. https:\/\/doi.org\/10.1002\/mus.21142.","journal-title":"Muscle Nerve"},{"issue":"2","key":"932_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/mus.25529","volume":"56","author":"JF Howard","year":"2017","unstructured":"Howard JF, Freimer M, O\u2019Brien F, et al. QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis. Muscle Nerve. 2017;56(2):328\u201330. https:\/\/doi.org\/10.1002\/mus.25529.","journal-title":"Muscle Nerve"},{"issue":"2","key":"932_CR18","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1002\/mus.26152","volume":"58","author":"J Vissing","year":"2018","unstructured":"Vissing J, O\u2019Brien F, Wang JJ, Howard JF. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study. Muscle Nerve. 2018;58(2):E21\u20132. https:\/\/doi.org\/10.1002\/mus.26152.","journal-title":"Muscle Nerve"},{"key":"932_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5146","volume":"341","author":"G Elwyn","year":"2010","unstructured":"Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing shared decision making in the NHS. BMJ. 2010;341:c5146. https:\/\/doi.org\/10.1136\/bmj.c5146.","journal-title":"BMJ"},{"issue":"2","key":"932_CR20","doi-asserted-by":"publisher","first-page":"W11","DOI":"10.1080\/15265161.2017.1409844","volume":"18","author":"PA Ubel","year":"2018","unstructured":"Ubel PA, Scherr KA, Fagerlin A. Autonomy: what\u2019s shared decision making Have to Do With It? Am J Bioeth. 2018;18(2):W11\u20132. https:\/\/doi.org\/10.1080\/15265161.2017.1409844.","journal-title":"Am J Bioeth"},{"key":"932_CR21","unstructured":"Amayra Caro I, Bargues Navarro G, Garc\u00eda Sanchoyerto M, Larrosa Dom\u00ednguez M, Rojas-Marcos Rodr\u00edguez de Quesada \u00cd. Gu\u00eda de recomendaciones pr\u00e1cticas en Enfermer\u00eda. Miastenia Gravis. Font\u00e1n Vinagre G, Larrosa Dom\u00ednguez M. Coordinadoras. Madrid: IM&C; 2024 Available from: https:\/\/www.colegioenfermeriahuesca.org\/wp-content\/uploads\/2024\/07\/grp-miastenia-gravis-compressed.pdf"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00932-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:34Z","timestamp":1778681254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00932-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00932-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana Vesperinas has received public speaking honoraria and compensation for advisory boards and consultation fees from argenx, UCB, Bial and Alexion. Elena Cort\u00e9s-Vicente has received public speaking honoraria and compensation for advisory boards and consultation fees from UCB, argenx, Alexion, Johnson and Johnson, Amgen and Lundbeck. Josep Rocaspana-Codana, David Reyes-Leiva, Marta Caballero-\u00c1vila, Alvaro Carbayo, Roger Collet-Vidiella, Laura Llans\u00f3, Eduard Gallardo, Joana Turon-Sans and Ricard Rojas-Garc\u00eda have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its subsequent amendments and has been approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau (code IIBSP-MIA-2023\u201303). All participants signed an informed consent for participation in the study and for the publication of anonymized data prior to their inclusion. The myMGverse APP is a medical device with CE marking in accordance with the Medical Devices Directive (MDD, 93\/42\/EEC).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}